INRLF Stock Price, Chart, Stats & News

Valneva SE
Save
Valneva SE (INRLF) does not currently pay a dividend.
460.84M
Market cap
–
Current P/E
666.67x
Forward P/E
INRLF chart
1M
3M
1Y
5Y
Loading chart...
About
Health care
Sector
Biotechnology
Industry
Valneva SE operates as a specialized biopharmaceutical entity, primarily focused on the creation and commercialization of preventative vaccines for infectious diseases where effective treatments are currently lacking. Its existing range of vaccines for international travelers includes IXIARO, an inactivated, Vero cell culture-based immunization designed to actively protect against Japanese encephalitis. Another key product is DUKORAL, an oral vaccine intended to prevent diarrhea caused by Vibrio cholera and/or the heat-labile toxin-producing Enterotoxigenic Escherichia coli.
Similar securities
Based on sector and market capitalization
Report issue





